Nestod Adalvo (Desmopressin Acetate)

Desmopressin acetate acts as a selective agonist at the V2 receptors located on the basolateral membrane of renal collecting‑duct cells. Activation of these receptors stimulates adenylate cyclase, raising intracellular cAMP, which drives the insertion of aquaporin‑2 water channels into the apical membrane. The result is increased water reabsorption, concentrated urine, and reduced diuresis.

The appropriate dose of Nestod Adalvo is individualized by the prescribing healthcare professional based on the patient’s age, weight, renal function, severity of the condition, and response to therapy. No fixed regimen is provided here; clinicians adjust the dose to achieve the desired antidiuretic effect while monitoring safety parameters such as serum sodium.

Desmopressin acetate is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if the potential benefit justifies any potential risk. Limited data are available for breastfeeding, so clinicians should weigh the benefits against possible exposure to the infant.

To place an order, submit an enquiry on the Nestod Adalvo product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After validation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Nestod Adalvo (desmopressin acetate) is a synthetic vasopressin analog that specifically targets V2 receptors, offering a more predictable antidiuretic effect than older agents such as vasopressin itself. Compared with non‑selective diuretics, it reduces urine output without causing electrolyte loss. Its oral tablet formulation provides convenient dosing, whereas some alternatives require intranasal or injectable routes.

Nestod Adalvo tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging to protect it from moisture and light. Do not store in areas with high humidity or direct sunlight, and keep out of reach of children.

Nestod Adalvo is taken orally as a tablet, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed, unless the prescriber provides specific instructions. Administration timing (e.g., before bedtime for nocturnal enuresis) is determined by the treating physician based on the individual’s condition.

The most serious adverse events involve severe hyponatremia and water intoxication, which can lead to seizures, coma, or pulmonary edema. Patients should be monitored for sudden changes in mental status, severe headache, nausea, vomiting, or swelling. Prompt medical evaluation is essential if any of these symptoms arise.

Nestod Adalvo is contraindicated in patients with known hypersensitivity to desmopressin or any excipients, in those with uncontrolled hyponatremia, and in individuals with severe renal impairment where fluid balance cannot be safely monitored. Caution is also advised for patients with chronic lung disease, heart failure, or conditions predisposing to fluid overload.